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ABSTRACT 
Importance: In patients investigated for suspected coronary heart disease (CHD), rates of invasive 
angiography are considered too high, with limited data from randomized trials evaluating 
strategies to reduce this. 
Objective: To test the hypothesis that in patients with suspected CHD, cardiovascular magnetic 
resonance (CMR)-guided care is superior to National Institute for Health and Care Excellence 
(NICE) guidelines-directed care and myocardial perfusion scintigraphy (MPS)-guided care, in 
reducing the occurrence of protocol-defined unnecessary angiography. 
Design, Setting and Participants: Multi-center, 3-parallel group, randomized trial using a 
pragmatic comparative effectiveness design. 1,202 symptomatic patients with suspected CHD and 
a pre-test likelihood 10-90%, were recruited from 6 UK hospitals. First randomization 23rd 
November 2012; last 12-month visit 12th March 2016. 
Intervention: Patients were randomly assigned (240:481:481) to management according to UK 
NICE Guidelines, or results of CMR, or MPS testing. 
Main Outcomes and Measures: The primary endpoint was protocol-defined unnecessary coronary 
angiography (Fractional Flow Reserve (FFR) >0.8 in all vessels ≥2.5mm diameter or by Quantitative 
Coronary Angiography (QCA) if FFR not feasible) within 12 months. Secondary endpoints included 
positive angiography, major adverse cardiovascular events (MACE), and procedural complications. 
Results: Patients mean(SD) age was 56.3(9.0) years, 564(46.9%) were women, mean pre-test 
likelihood was 49.5%(23.8%). After 12 months 102, 85 and 78 patients underwent invasive 
coronary angiography in the NICE, CMR and MPS-guided care groups; study-defined unnecessary 
angiography occurred in 69(28.8%), 36(7.5%) and 34(7.1%) patients respectively. Adjusted odds 
ratio of unnecessary angiography for CMR vs. NICE guided-care was 0.21 (95%CI: 0.12 to 0.34; 
p<0.001) and for CMR vs. MPS 1.27 (0.79 to 2.03; p=0.32). Positive angiography proportions were 
12.1% (8.2% to 16.9%), 9.8% (95%CI: 7.3% to 12.8%), 8.7% (6.4% to 11.6%), respectively. MACE 
were reported in 1.7, 2.5% and 2.5% of patients respectively at minimum 12 months, adjusted 
hazard ratios: CMR vs. NICE 1.37 (95%CI 0.52 to 3.57); CMR vs. MPS: 0.95 (0.46 to 1.95). 
Conclusions and Relevance: In patients with suspected angina, investigation by CMR produced a 
lower probability of unnecessary angiography than NICE guideline-directed care, with no 
statistically significant difference between CMR and MPS strategies. There were no statistically 
significant differences in MACE rates at 12 months post-randomization. 
Trial Registration: clinicaltrials.gov: NCT01664858 
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KEY POINTS: 
Question: In patients investigated for suspected coronary heart disease, does a strategy involving 
Cardiovascular Magnetic Resonance (CMR) result in less unnecessary angiography than a 
Myocardial Perfusion Scintigraphy (MPS) strategy or a national guideline that included direct-to-
angiography for high-risk patients? 
Findings: In this clinical trial, both CMR and MPS significantly reduced unnecessary angiography 
rates compared to national guidelines (7.5%, 7.1%, 28.8%, respectively); no statistically significant 
differences were seen between CMR and MPS. There was no statistically significant difference in 
MACE rates at 12-months between the 3 groups. 
Meaning: Non-invasive functional imaging strategies reduced unnecessary angiography compared 
to guidelines-directed care.  
  
BACKGROUND 
Coronary heart disease (CHD) is a leading cause of death and disability worldwide. Several 
investigations are available to diagnose CHD, risk-stratify patients and determine the need for 
revascularization. Myocardial perfusion scintigraphy (MPS) by single-photon emission computed 
tomography is the most commonly used test worldwide for the assessment of myocardial 
ischemia, with robust evidence supporting its prognostic value. However, cardiovascular magnetic 
resonance (CMR) is increasingly recognized as having excellent diagnostic accuracy and prognostic 
value.1,2  
Despite the widespread availability and recommendations for non-invasive imaging in 
international guidelines,3-5 invasive coronary angiography is commonly used early in diagnostic 
pathways in patients with suspected CHD. Evidence from large populations presenting with chest 
pain has confirmed that the majority will not have significant obstructive coronary disease;6,7 a 
large US study reported that ~60% of elective cardiac catheterizations found no obstructive CHD.8 
Thus, avoiding unnecessary angiography should reduce patient risk and provide significant 
financial savings. 
Current guidelines for investigation of stable chest pain advocate management based on the pre-
test likelihood of CHD.3-5 However, pre-test likelihood models can overestimate CHD risk, 
therefore paradoxically increasing the probability of invasive coronary angiography.9 To date, 
there are no large scale comparative effectiveness trials of different functional imaging strategies 
recommended by current guidelines. 
The Clinical Evaluation of MAgnetic Resonance imaging in Coronary heart disease 2 trial (CE-MARC 
2) was designed to test the hypothesis that in patients with suspected CHD, CMR-guided care is 
superior to guidelines-directed care4 and MPS-guided care,10 in reducing the occurrence of 




CE-MARC 2 was a multi-center, 3-parallel group, randomized trial. It used a pragmatic comparative 
effectiveness design,11 to determine efficacy and safety of three strategies (CMR-guided care, 
MPS-guided care (following ACCF/AHA appropriate-use criteria)10, and UK National Institute for 
Health and Care Excellence (NICE) guidelines (CG95)4) for investigating patients with suspected 
CHD. The study was conducted in accordance with the protocol (available with the full text of this 
article) which was approved by the UK National Research Ethics Service (12/YH/0404) and 
institutional review boards of the participating centers. Study conduct was in accordance with the 
Declaration of Helsinki; all patients provided written informed consent. The study protocol and 
statistical analysis plan are available as an online supplement to the article.  
TRIAL POPULATION 
Patients with suspected angina pectoris were eligible if they were aged ≥30 years, had a CHD pre-
test likelihood of 10-90%,4,12 and suitable for revascularization. Exclusion criteria included non-
anginal chest pain, normal MPS/cardiac computed tomography (CCT) within previous 2-years, 
clinically unstable, previous myocardial infarction, previous coronary revascularization and 
contraindication to any study non-invasive imaging test (Supplementary Appendix Table S4).11 
Self-reported ethnicity was collected as a known cardiac risk factor. 
RANDOMIZATION 
Patients were assigned using minimization, incorporating a random element and 1:2:2 allocation 
ratio13 through an automated 24h secure-access telephone service by the Clinical Trials Unit. 
Allocation was to 1 of 5 equally-sized groups (A:B:C:D:E, stratifying on center, age (30-64,≥65yrs), 
pre-test likelihood (10-29%,30-60%,61-90%) and sex) following which management was by NICE 
guidelines-directed care (A) CMR (groups B or C) or MPS (D or E). Patients randomized to NICE-
directed care were scheduled for CCT, MPS or direct to coronary angiography for those with pre-
test likelihoods of 10-29%, 30-60%, and 61-90% respectively.  
DIAGNOSTIC TESTING 
All investigations were performed and interpreted by certified local physicians using protocols 
conforming to international standards.14-17 Quality Assurance was undertaken centrally 
throughout the trial by blinded, independent, modality-specific imaging experts (Supplementary 
Appendix Table S3): 10% of scans for each modality at each recruiting center were centrally 
reviewed for image quality and report accuracy. Detailed protocols for each imaging modality and 
criteria for reporting a positive result have been published; 11 a positive CMR, MPS or CCT resulted 
in protocol-defined invasive coronary angiography and fractional flow reserve (FFR) 
measurement.11 FFR (PressureWireTM, St Jude Medical, Minneapolis, USA) was performed in all 
vessels ≥2.5mm with a 40-90% stenosis.11 Where FFR was not possible for clinical/safety reasons, 
quantitative coronary angiography (QCA) was performed. All FFR and QCA results were analyzed at 
the Glasgow Angiographic Core-Lab by a single, independent, blinded observer. Positive 
angiography defined as any lesion with FFR≤0.8, or if FFR not performed, a percentage diameter 
stenosis of ≥70% in one view or ≥50% in two orthogonal views. 
ENDPOINTS 
The primary endpoint was protocol-defined unnecessary coronary angiography occurring within 
12 months, defined by a normal FFR (or QCA) in all vessels ≥2.5mm diameter. By design this 
included any unnecessary angiography occurring after a false positive test result, direct to 
angiography for high-pre-test likelihood patients (NICE group only), and imaging results which 
were either inconclusive or negative but over-ruled by the responsible physician.11 Secondary 
endpoints included a composite of major cardiovascular events (MACE: cardiovascular death, 
myocardial infarction, unplanned coronary revascularization and hospital admission for 
cardiovascular cause), and positive angiography rates (recommended by the independent Data 
Monitoring and Ethics Committee (DMEC)). Complications directly related to trial investigations 
resulting in prolonged hospital stay/specific treatment were pre-specified as safety secondary 
endpoints. Quality of life outcomes and cost effectiveness analyses will be reported subsequently. 
TRIAL OVERSIGHT 
Independent DMEC and Trial Steering Committee (TSC) assessed study conduct, integrity and 
safety 6-monthly (Supplementary Appendix Table S2). 
STATISTICAL ANALYSIS 
1200 patients, allowing for 20% non-completion, would provide the study with 99% power to 
detect a difference in unnecessary angiography between CMR and guidelines-directed care (using 
2:1 allocation), and 94% power between CMR and MPS-guided care based on projected 
unnecessary angiography proportions of 4.5%, 11.7% and 30% in the CMR, MPS and NICE-groups 
respectively (2-sided 5% significance for continuity-corrected chi-squared test).18  
Logistic regressions were used to model odds of an unnecessary angiogram for CMR- versus both 
NICE- and MPS-guided management, including stratification factors (treating centers as fixed 
effects). Analyses used intention-to-treat (ITT) populations and were repeated in per-protocol 
populations. Multiple imputation (by fully conditional specification) was used for missing baseline, 
test and endpoint data to ensure all participants could be included in the analysis, and avoid 
treating unknown values as certainly known (e.g. with mean imputation, no-event imputation).19 
Ten fully-imputed analysis datasets were generated - since the proportion of patients with any 
missing data was less than 10% - and primary endpoint analyses on each dataset were combined 
to produce the overall ITT effect using Rubin’s rules. The proportion of patients in each group with 
a MACE at twelve months and absolute differences in MACE rates were calculated. Confidence 
intervals for proportions and their differences were calculated by exact methods. Time to first 
MACE was modelled using Cox proportional hazards regression, including stratification and other 
pre-specified (Hypertension, Ethnicity, Smoking and Diabetes) factors and illustrated using Kaplan-
Meier estimates. CMR and MPS groups were combined into a single ‘functional imaging’ group to 
compare unnecessary angiography versus guidelines-directed care in the 61-90% and 10-29% pre-
test likelihood subgroups. Subgroup analyses were undertaken by including interaction effects in 
regression models. Statistical tests were 2-sided and called significant at the 5% level. Analyses 
used SAS v9.4 (SAS Institute Inc.) after all randomized patients had completed 12 months follow-




Between November 2012 and March 2015, 13,957 patients were screened of whom 2,205 were 
eligible (Figure 1 lists reasons for non-eligibility and non-consent). 1,202 (55% of eligible) patients 
were recruited from six UK centers (Leeds, Glasgow, Leicester, Bristol, Oxford, London (St 
Georges)) and allocated to guidelines-directed care (n=240) or management by CMR (n=481) or 
MPS (n=481) (Figure 1). 
BASELINE CHARACTERISTICS  
Mean(SD) age of patients was 56.3(9.0) years, 638(53%) were male, mean BMI 29.1(5.2) and 
1,107(92%) were classified ethnically as white (Table 1). The study population had a substantial 
burden of cardiovascular risk factors: 150(12.5%) of the patients had diabetes, 458(38.1%) had 
hypertension, 702(58.4%) were past or current tobacco users, 483(40.2%) had dyslipidemia, and 
651(54.2%) had a family history of premature CHD. Patients had a median of 2 of these 5 risk 
factors. All patients were symptomatic, with 401(33.4%) reporting typical chest pain and 
801(66.6%) atypical chest pain as their primary symptom. The assessment of cardiac risk, 
calculated according to the 2013 atherosclerotic cardiovascular disease risk score from the 
ACCF/AHA guidelines, showed that 441 of 923 (47.8%) patients had a 10-year risk of events of 
7.5% or higher.20 The mean(SD) pre-test likelihood of obstructive CHD according to the Duke Score 
was 49.5(23.8%).12 
TEST CONDUCT 
Of 481 patients assigned to the CMR strategy, 435(90.4%) had CMR as the initial test 
(median(Interquartile Range) time from randomization 20(13-34) days), 5(1.0%) had MPS, 5(1.0%) 
went directly to angiography and 23(4.8%) had no test. Of 481 patients assigned to the MPS 
strategy, 446(92.7%) had MPS as the initial test (time from randomization 28(22-39) days), 4(0.8%) 
had CMR, 5(1.0%) went directly to angiography and 21(4.4%) had no test. Of 240 patients assigned 
to NICE guidelines strategy 56(23.3%) had CCT (time from randomization 34(14-44) days), 
86(35.8%) had MPS, 85(35.4%) went directly to angiography and 11(4.6%) had no test. The 
numbers of patients adherent to receiving both their initial randomized test and per-protocol 
compliance with their test result were 414(86.1%), 368(76.5%) and 200(83.3%), respectively. 
Study sites reported their interpretation of the initial test as positive for CHD in 54/435(12.4%) 
patients in the CMR group, in 81/446(18.2%) patients in the MPS group and in 19/142(13.4%) 
patients in the NICE group. There was no difference in revascularization rates (Figure 1) between 
the 3 groups (P=0.47). The rate of patients with incomplete data required for analysis of the 
primary endpoint was low: 18/240(7.5%), 50/481(10.4%) and 33/481(6.9%) for NICE, CMR and 
MPS groups, respectively. Of these, 11/240(4.6%), 23/481(4.8%) and 21/481(4.4%) were related to 
missing test results for NICE, CMR and MPS groups, respectively. 
PRIMARY ENDPOINT 
Overall, 265(22.0%) patients underwent at least one coronary angiogram (10 patients underwent 
2 angiograms) within 12 months of randomization: 102/240(42.5%) in the NICE group, 
85/481(17.7%) in the CMR group and 78/481(16.2%) in the MPS group. The primary endpoint of 
unnecessary angiography occurred in 69(28.8%), 36(7.5%) and 34(7.1%) and patients respectively. 
98(70.5%) of these angiograms had no visual stenosis and were not assessed further, 40(28.8%) 
reached the conclusion by FFR and 1(0.7%) involved QCA only. The adjusted odds ratio (95%CI) of 
unnecessary angiography for CMR versus NICE was 0.21 (0.12 to 0.34; P<0.001) and CMR versus 
MPS 1.27 (0.79 to 2.03; P=0.32). Table 2 shows individual components of the primary endpoint. 
For both comparisons, the primary analysis was repeated in the per-protocol population, with no 
effect on the trial results. Sensitivity analyses using random center effects or adjusting for further 
risk factors (hypertension, ethnicity, smoking status) or using the per-protocol population did not 
change overall trial conclusions (Supplementary Appendix Table S5). Exploratory subgroup 
analyses showed consistent results across subgroups (Figure 2).  
SECONDARY ENDPOINTS 
Positive angiography was observed in 29(12.1%)(95%CI 8.2% to 16.9%), 47(9.8%)(95%CI 7.3% to 
12.8%) and 42(8.7%)(95%CI 6.4% to 11.6%) patients for NICE, CMR and MPS groups respectively 
(P=0.36). During minimum 1-year follow-up (median 15.8 months, Interquartile range 12.1 to 
24.2), 36(3.0%) patients had at least one MACE: NICE 6(2.5%), CMR 15(3.1%), MPS 15(3.1%) (Table 
2). Annualized MACE rates were 1.6%, 2.0% and 2.0%, respectively. Adjusted hazard ratios for 
MACE were: CMR vs. NICE 1.37 (95%CI: 0.52 to 3.57; P=0.52); CMR vs. MPS 0.95 (0.46 to 1.95; 
P=0.88). Hard events (cardiovascular death and MI) occurred in 3(1.3%), 5(1.0%), 4(0.8%) in NICE, 
CMR and MPS groups respectively (P=0.93). Figure 3 shows the Kaplan-Meier cumulative incidence 
estimate of first MACE. Five test complications were reported: CMR (1: mild urticarial reaction), 
MPS (0), cardiac CT (1: vasovagal episode) and angiography (3: ventricular tachycardia; pseudo-
aneurysm & popliteal DVT; right coronary artery spasm & transient ST elevation). 
FUNCTIONAL IMAGING ASSESSMENT 
Using functional imaging first-line (CMR or MPS) in patients with 61-90% (high) pre-test likelihood 
of CHD, resulted in substantially reduced odds of unnecessary angiography compared to the NICE 
group; odds ratio (OR) 0.048 (0.023 to 0.10; P<0.001). Among those with <30% (low) pre-test 
likelihood, the odds of unnecessary angiography were also numerically lower by a functional 
imaging approach compared to anatomical (CCT) assessment (OR 0.44; 0.17 to 1.17; P=0.099). 
 
DISCUSSION 
CE-MARC 2 was a multi-center, randomized trial in a large community-based population of 
symptomatic patients undergoing assessment for suspected CHD, in whom further investigation 
was appropriate according to international guidelines. A CMR-guided strategy significantly 
reduced unnecessary angiography occurrence, as compared with NICE guidelines-guided care, but 
was not significantly different from an MPS-guided strategy (following US appropriate use 
criteria).10 There was no difference in short-term MACE rates or disease detection (positive 
angiography) rates, between the three strategies. 
There is concern that coronary angiography is over-used in the diagnostic pathway of suspected 
CHD, and that the majority of patients investigated will not have significant obstructive coronary 
disease.6,7 Avoiding unnecessary invasive angiography could have significant financial benefits, 
avoids exposing patients to unnecessary risk, and is also a strong patient desire.21 For this reason 
we chose this as our patient-focused primary endpoint.  
Current international guidelines for investigation and management of suspected CHD all suggest 
risk stratification for PTL estimation.12,22,23 The Duke score, used in NICE guidelines, is based upon 
the original Diamond Forrester model, but includes additional demographic factors to further 
stratify risk.12 These models, derived over three-decades ago, tend to over-estimate CHD risk, as 
patient demographics, risk factors and treatment have changed considerably over time.24 In CE-
MARC 2, the reduction in unnecessary angiography by a CMR (or MPS) strategy appears largely 
driven by the over-estimation of disease probability from using the Duke score. Current NICE 
guidelines categorize a pre-test likelihood of 60-90% as being high-risk for CHD, and recommend 
direct referral for angiography. In CE-MARC 2 this explained the majority of patients in the NICE-
guided group who got referred for angiography (82/102; 80.4%), and the majority of unnecessary 
angiograms (59/69; 85.5%). This is further emphasized by the pre-planned, combined sub-analysis 
of functional imaging (CMR or MPS) in the 60-90% (high-risk) PTL population, which showed 
substantially reduced odds of unnecessary angiography in this group compared to NICE guideline-
based care.  
Overall, rates of disease detection (positive angiography) were comparable for the three 
strategies, suggesting no penalty for using functional imaging as a gatekeeper for angiography, 
even in high-risk subgroups. Consistent with published studies, CE-MARC 2 showed a low overall 
rate of MACE in a stable chest pain population, with no early difference between strategies. 
It remains a point of debate as to whether all of our protocol-defined unnecessary angiograms are 
truly clinically unnecessary; some would argue that negative tests are the ‘price to pay’ for not 
missing important disease in others. This assumes a population perspective, and our trial primary 
endpoint was derived after close consultation with patient and public representatives: from an 
individual patient perspective, an angiogram that doesn’t change their treatment or their clinical 
outcome is considered by patients to have been unnecessary. Certainly guidelines are clear that 
we do not need to undertake angiography to either diagnose angina or offer primary prevention 
and symptom control.  
There have been no randomized trials comparing the performance of current management 
guidelines and a broad functional imaging approach in terms of important clinical endpoints. 
Although cross-sectional imaging (CMR and CCT) has improved our diagnostic ability, benefits in 
terms of health outcomes are harder to demonstrate, partly due to complexity of subsequent 
treatment effects. Functional versus anatomical assessment as a potential ‘gate-keeper’ to the 
catheterization laboratory is a topic of on-going debate.25,26 The PROMISE trial showed no 
improvement in clinical outcomes using CCT versus a variety of functional tests in patients 
investigated for suspected CHD; whilst the CCT strategy increased rates of cardiac catheterization 
(12.2% vs. 8.1%; P=0.02) and coronary revascularization.25 This may be important following a 
recent observational study of 544 US centers showing higher rates of inappropriate percutaneous 
coronary intervention at sites performing the highest rates of angiography, suggesting anatomical 
assessment could predispose to unnecessary therapy.27 Although numbers are small, in CE-MARC 
2 an increased rate of unnecessary angiography was suggested in the low-risk group in the 
guidelines-based strategy group, the majority of whom underwent CCT. 
Limitations: 
The false positive and false negative rates are often quantities of interest in evaluating diagnostic 
methods. CE-MARC 2 only angiographically verified a subset of patients, contingent on strategy 
findings, and so cannot provide accurate estimates. The original CE-MARC trial defined the false 
positive and false negative rates for CMR and MPS, and showed CMR was superior to MPS.1 In the 
current study there was no statistical difference between CMR and MPS strategies for reduction in 
unnecessary angiography, despite the finding from CE-MARC. However, CE-MARC was able to 
detect small differences due to its paired design (all patients underwent all tests), whereas the 
current study compared independent groups which confers lower power.  
The study population was predominantly white northern European, therefore findings may not 
translate to other populations; geographic heterogeneity of CHD incidence is well known.23 At trial 
initiation, contemporary guidelines used the Duke score,3,4 with the NICE guidelines classifying 
high risk for CHD as 60-90% pre-test likelihood. It is now recognized that this may overestimate 
CHD risk, such that recent guidelines5 have adopted a recalibrated risk model.23 The primary 
endpoint was objective (using FFR), although performance was not clinically possible in all cases; 
blinded core-lab analysis of QCA data avoided subjective visual angiography interpretation. Overall 
full adherence to the protocol was high, with some unavoidable variation due to individual clinical 
practice which could introduce bias (e.g. abnormal imaging results not proceeding to 
angiography). To mitigate this, analysis was by ITT principles and the primary endpoint was 
purposely all-inclusive (i.e. false positives, true negatives when not believed by clinicians, and also 
test failures). The slightly different rates of incomplete data (not statistically significant) between 
study groups was not of concern, as the data completeness rate was however high overall. Per-
protocol and sensitivity analyses (Table S5) did not alter the trial conclusions. Finally, although 
clinically robust, MACE isn’t a proxy for a missed diagnosis/treatment, e.g. missed opportunity for 
revascularization by not having angiography (due to a false negative result). However, it remains 
debatable whether revascularization for stable angina has prognostic benefit over optimal medical 
therapy, which will be answered by the ongoing ISCHEMIA trial.28  
Conclusions: 
In patients with suspected angina, investigation by CMR produced a lower probability of 
unnecessary angiography than NICE guideline-directed care, with no statistically significant 
difference between CMR and MPS strategies. There were no statistically significant differences in 
MACE rates at 12 months post-randomization. 
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Table 1. Baseline characteristics of the trial participants by study group. 







Age, Mean (SD) years 56.3 (9.03) 56.5 (9.21) 56.5 (9.10) 55.9 (8.87) 
Female sex, no. (%) 564 (46.9%) 112 (46.7%) 227 (47.2%) 225 (46.8%) 
Non-white Ethnicity, no. (%) 95 (7.9%) 19 (7.9%) 38 (7.9%) 38 (7.9%) 
Cardiac risk factors         
Body Mass Index, Mean (SD) kg/m2 29.1 (5.23) 29.0 (5.24) 29.2 (5.36) 29.1 (5.12) 
Hypertension, no. (%) 458 (38.1%) 99 (41.3%) 177 (36.8%) 182 (37.8%) 
Diabetes, no. (%) 150 (12.5%) 24 (10.0%) 53 (11.0%) 73 (15.2%) 
Dyslipidemia, no. (%) 483 (40.2%) 99 (41.3%) 186 (38.7%) 198 (41.2%) 
Current or past Smoking, no. (%) 702 (58.4%) 147 (61.3%) 284 (59.0%) 271 (56.3%) 
Family history of premature CHD* 651 (54.2%) 140 (58.3%) 252 (52.4%) 259 (53.8%) 
Peripheral Vascular Disease, no. (%) 27 (2.2%) 10 (4.2%) 8 (1.7%) 9 (1.9%) 
Cerebrovascular disease, no. (%) 42 (3.5%) 8 (3.3%) 17 (3.5%) 17 (3.5%) 
Nature of Angina, no. (%)         
Atypical 801 (66.6%) 158 (65.8%) 318 (66.1%) 325 (67.6%) 
Typical 401 (33.4%) 82 (34.2%) 163 (33.9%) 156 (32.4%) 
Risk Burden         
PTL, Mean (SD) %† 49.5% (23.78%) 50.7% (23.28%) 49.9% (24.25%) 48.6% (23.57%) 
PTL 10-29%†† 314 (26.1%) 61 (25.4%) 128 (26.6%) 125 (26.0%) 
PTL 30-60%†† 450 (37.4%) 88 (36.7%) 179 (37.2%) 183 (38.0%) 
PTL 61-90%†† 438 (36.4%) 91 (37.9%) 174 (36.2%) 173 (36.0%) 
No. risk factors/patient, Mean (SD) 2.0 (1.13) 2.1 (1.05) 2.0 (1.18) 2.0 (1.11) 
10yr ASCVD risk >7.5%‡ 441/923 (47.8%) 93/179 (52.0%) 175/377 (46.4%) 173/367 (47.1%) 
Medications, no. (%)         
Antiplatelet therapy 689 (57.3%) 150 (62.5%) 271 (56.3%) 268 (55.7%) 
Beta Blocker 381 (31.7%) 74 (30.8%) 150 (31.2%) 157 (32.6%) 
Statin or other lipid lowering therapy 500 (41.6%) 108 (45.0%) 191 (39.7%) 201 (41.8%) 
Angiotensin Converting Enzyme 
inhibitor or Angiotensin II Receptor 
Blocker 
303 (25.2%) 66 (27.5%) 115 (23.9%) 122 (25.4%) 
Other anti-anginal medication 701 (58.3%) 142 (59.2%) 283 (58.8%) 276 (57.4%) 
 
* Family history of premature CHD defined as diagnosis of the disease in a male first-degree relative before 
55 years of age or in a female first-degree relative before 65 years of age.  
† According to Pryor et al.12  
†† Categories used to decide stratification in the NICE Guidelines group.  
‡ According to edibility criteria of Goff et al.20 
ASCVD, atherosclerotic cardiovascular disease; ACE, angiotensin converting enzyme; ARB, angiotensin II 
receptor blocker.  
Table 2. Summary of trial endpoints. 
     Absolute Differences  

















Components of the primary endpoint 
False positive non-invasive test 35 5 18 12 - - 
Direct to angiography (by 
strategy) 
59 59 - - - - 
Negative test, non per-protocol 41 5 15 21 - - 
Inconclusive test/result 4 - 3 1 - - 
 
Secondary endpoints 





False positive non-invasive test 73 4 38 31 - - 
Direct to angiography (by 
strategy) 
23 23 - - - - 
Negative non-invasive test, non 
per-protocol 
9 1 2 6 - - 
Inconclusive non-invasive 
test/result 
2 - 2 - - - 
Acute/urgent Angio indication 9 1 4 4 - - 
Angio as alternative initial 
investigation 
2 - 1 1 - - 
       
Major Adverse Cardiovascular Events 




Cardiovascular death 5 1* 1 3 - - 
Myocardial Infarction 9 2 5 2 - - 
Revascularization - Unplanned 
PCI 
12 2 6 4 - - 
Revascularization - Unplanned 
CABG 
1 - 1 - - - 
Arrhythmia 9 2 4 3 - - 
Heart Failure 4 - - 4 - - 
Stroke/TIA 4 - 3 1 - - 
* This event occurred 2 days after the 3-year cut-off, so is excluded from summaries of absolute MACE 
rates at 3 years. All other events occurred within 3 years of randomization. # 3-year MACE rates include all 
participants (median follow-up 16 months). PCI, Percutaneous Coronary Intervention; CABG, Coronary 
Artery Bypass Graft; TIA Transient Ischemic Attack 
 
  
Figure 1. Patient flow diagram  
 
ACS, acute coronary syndrome; MI, myocardial infarction; CMR, cardiovascular magnetic resonance; MPS 
myocardial perfusion scintigraphy; CCT, cardiac computed tomography; ETT, exercise treadmill test; DSE, 
dobutamine stress echo; PCI, percutaneous coronary intervention, CABG, coronary artery bypass grafting; ITT, 
intention to treat; *patients may have received more than one test, in addition to or as an alternative to their 
strategy.   
Figure 2. Forest plots for the effect of gender, age, ethnicity, hypertension, smoking, diabetes, 
family history and body mass index, for A) CMR vs. NICE, B) CMR vs. MPS. 
 
 
Unnecessary angiography figures quoted are the frequencies observed within each subgroup.   
Figure 3. Kaplan-Meier event curves for time to first MACE after a minimum of 12 month follow up 
from randomization (median 16 months). 
 
Hazard ratios for time to first MACE (and Likelihood Ratio test P-Values) calculated by Cox 
Proportional hazards modelling, adjusted for randomizing center, age category, sex, pre-test 
likelihood category, hypertension, ethnicity, diabetes, and smoking status. 
